KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $16.4 million.

  • Sarepta Therapeutics' Share-based Compensation fell 6653.6% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year decrease of 1830.69%. This contributed to the annual value of $205.1 million for FY2024, which is 1239.3% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Share-based Compensation is $16.4 million, which was down 6653.6% from $41.6 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Share-based Compensation registered a high of $102.9 million during Q2 2022, and its lowest value of $16.4 million during Q3 2025.
  • In the last 5 years, Sarepta Therapeutics' Share-based Compensation had a median value of $45.8 million in 2023 and averaged $44.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 25480.0% in 2022, then plummeted by 6653.6% in 2025.
  • Sarepta Therapeutics' Share-based Compensation (Quarter) stood at $29.7 million in 2021, then soared by 69.82% to $50.5 million in 2022, then fell by 9.3% to $45.8 million in 2023, then increased by 20.66% to $55.3 million in 2024, then plummeted by 70.34% to $16.4 million in 2025.
  • Its Share-based Compensation stands at $16.4 million for Q3 2025, versus $41.6 million for Q2 2025 and $46.6 million for Q1 2025.